natgillin/translations-raw huggingface dataset:
Get medical help immediately if you get the following symptoms, as they may be signs of a heart attack or decreased blood flow to the heart: chest discomfort or pain which may spread beyond your chest to your shoulders, arms, back, neck, teeth, jaw or stomach and may come and go; shortness of breath; sudden outbreak into a sweat with cold, clammy skin, feeling dizzy or fainting. 
Takoj poiščite medicinsko pomoč, če se vam pojavijo naslednji simptomi, ker so lahko znak srčnega napada ali zmanjšane preskrbe srca s krvjo: neprijeten občutek v prsnem košu ali bolečina, ki se lahko širi od prsnega koša v ramo, roko, hrbet, vrat, zobe, čeljusti ali želodec in se lahko pojavi ter izgine, kratka sapa, nenadno znojenje z mrzlico, vlažna koža, občutek omotičnosti ali omedlevice.
Other strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbital and St. John's wort) may also increase metabolism of regorafenib. 
Tudi drugi močni zaviralci CYP3A4 (npr. fenitoin, karbamazepin, fenobarbital in šentjanževka) lahko povečajo presnovo regorafeniba.
Inhibitors and inducers of BCRP and P-glycoprotein may interfere with the exposure of M-2 and M-5. 
Zaviralci in induktorji BCRP in glikoproteina P lahko vplivajo na izpostavljenost presnovkoma M-2 in M-5.
The adverse drug reactions reported in clinical trials in patients treated with Stivarga are shown in Table 3. 
Neželeni učinki, o katerih so poročali v kliničnih preskušanjih pri bolnikih, zdravljenih z zdravilom Stivarga, so navedeni v preglednici 3.
Following oral administration, mean elimination half-life for regorafenib and its metabolite M-2 in plasma ranges from 20 to 30 hours in different studies. 
Po peroralni uporabi je bil v različnih študijah povprečni razpolovni čas izločanja regorafeniba in njegovega presnovka M-2 v plazmi od 20 do 30 ur.
White opaque HDPE bottle closed with a PP/PP (polypropylene) screw cap with sealing insert and a molecular sieve desiccant. 
Bela, motna HDPE plastenka, zaprta s PP/PP (polipropilen) navojno zaporko s tesnilnim vložkom in sušilnim sredstvom (molekularno sito).
Regorafenib is eliminated mainly via the hepatic route. 
Regorafenib se izloča predvsem skozi jetra.
Avoid becoming pregnant while being treated with Stivarga, as this medicine may harm your unborn baby. 
Med zdravljenjem z zdravilom Stivarga ne smete zanositi, ker to zdravilo lahko škoduje vašemu nerojenemu otroku.
Parent compound found in faeces could be derived from intestinal degradation of glucuronides or reduction of metabolite M-2 (N-oxide), as well as unabsorbed regorafenib. 
Izhodna spojina v blatu je lahko posledica razgradnje glukuronidov ali redukcije presnovka M-2 (N-oksid) kot tudi neabsorbiranega zdravila.
Plasma concentration-time profiles for regorafenib as well as for the major circulating metabolites showed multiple peaks across the 24-hour dosing interval, which are attributed to enterohepatic circulation. 
Profil plazemske koncentracije v odvisnosti od časa je za regorafenib in glavne presnovke, ki krožijo v krvnem obtoku, pokazal več vrhov v 24-urnem intervalu odmerjanja, pri čemer se vsi pripisujejo enterohepatičnemu obtoku.
NA Best Supportive Care Hazard ratio < 1 favours Stivarga ** based on investigator's assessment of tumour response by modified RECIST Response rate (complete or partial response), DCR (complete response, partial response and stable disease maintained for 6 weeks) 
§ najboljša podporna oskrba * razmerje ogroženosti < 1 v prid zdravila Stivarga ** tumorski odziv po modifikaciji RECIST glede na oceno # stopnja odziva (popolni ali delni odgovor), stopnja nadzora nad boleznijo (popolni odgovor,
Monitor liver function weekly until transaminases return to <3 times ULN (Grade 1) or baseline. 
Delovanje jeter je treba spremljati vsak teden, dokler se vrednosti transaminaz ne vrnejo na < 3-kratnik ULN (stopnja 1) ali na izhodiščne vrednosti.
In cases of worsening infection events, interruption of Stivarga treatment should be considered. 
V primerih poslabšanja okužb je treba razmisliti o prekinitvi zdravljenja z zdravilom Stivarga.
Fatal outcomes associated with infection were observed more often in patients treated with Stivarga (1.0%), compared to patients receiving placebo (0.3%), and were mainly respiratory events. 
Smrtne izide, povezane z okužbami, so pogosteje opazili pri bolnikih, zdravljenih z zdravilom Stivarga (1,0 %) v primerjavi z bolniki, ki so prejemali placebo (0,3 %) in so imeli predvsem zaplete v dihalih.
- reduction in the number of blood platelets, characterised by easy bruising or bleeding 
- zmanjšano število krvnih ploščic s simptomi, za katere je značilno hitro nastajanje podplutb ali krvavitve (trombocitopenija)
In cases of severe or persistent hypertension despite adequate medical management, treatment should be temporarily interrupted and/or the dose reduced at the discretion of the physician (see section 4.2). 
V primerih hude ali vztrajne hipertenzije, kljub ustreznim medicinskim ukrepom, je treba po presoji zdravnika zdravljenje začasno prekiniti in/ali zmanjšati odmerek (glejte poglavje 4.2).
Regorafenib, M-2 and M-5 are likely to undergo enterohepatic circulation (see section 5.2). 
Regorafenib, presnovka M-2 in M-5 običajno prehajajo v enterohepatični obtok (glejte poglavje 5.2).
The DCR (complete response or partial response or stable disease) was significantly higher in patients treated with Stivarga (41.0% vs. 14.9%, p<0.000001, 1 sided). 
Stopnja nadzora nad boleznijo (popoln ali delni odgovor ali stabilna bolezen) je bila pomembno višja pri bolnikih, zdravljenih z zdravilom Stivarga (41,0 % v primerjavi s 14,9 %, p < 0,000001, 1-stransko).
28 film-coated tablets 84 (3 x 28) film-coated tablets 
FARMACEVTSKA OBLIKA IN VSEBINA 28 filmsko obloženih tablet 84 (3 x 28) filmsko obloženih tablet
Posterior reversible encephalopathy syndrome (PRES) PRES has been reported in association with Stivarga treatment (see section 4.8). 
Sindrom posteriorne reverzibilne encefalopatije (PRES - Posterior reversible encephalopathy syndrome) V povezavi z zdravljenjem z zdravilom Stivarga so poročali o PRES (glejte poglavje 4.8).
4.8 months 
4,8 mesecev
The desiccant is a moisture absorbing material filled in a small container to protect the tablets from moisture. 
Sušilno sredstvo, ki veže vodo, se nahaja v majhnem vsebniku in ščiti tablete pred vlago.
Mechanism of action and pharmacodynamic effects Regorafenib is an oral tumour deactivation agent that potently blocks multiple protein kinases, including kinases involved in tumour angiogenesis (VEGFR1, -2, -3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF, BRAFV600E), metastasis (VEGFR3, PDGFR, FGFR) and tumour immunity (CSF1R). 
Regorafenib je peroralno zdravilo za zaviranje rasti tumorjev, ki močno zavira multiple proteinkinaze, vključno s kinazami, ki sodelujejo pri angiogenezi (VEGFR1, -2, -3, TIE2), onkogenezi (KIT, RET, RAF-1, BRAF, BRAFV600E), razsoju rakavega tkiva (VEGFR3, PDGFR, FGFR) in tumorski imunosti (CSF1R).
Table 2: Recommended measures and dose modifications in case of drug-related liver function test abnormalities 
Preglednica 2: Priporočeni ukrepi in spremembe odmerkov v primeru odstopanj v izvidih preiskav delovanja jeter, ki so povezani z zdravilom
Main findings consisted of malformations of the urinary system, the heart and major vessels, and the skeleton. 
Glavni izsledki so bili deformacije sečil, srca in velikih žil ter okostja.
Each daily dose of 160 mg contains 1.68 mg of lecithin (derived from soya) (see section 4.4). 
En dnevni odmerek 160 mg vsebuje 1,68 mg lecitina (pridobljenega iz soje) (glejte poglavje 4.4).
Both metabolites, M-2 and M-5, exhibit non-linear accumulation, which might be caused by enterohepatic recycling or saturation of the UGT1A9 pathway. 
Oba presnovka, M-2 in M-5, se kopičita nelinearno, kar je lahko posledica enterohepatičnega kroženja ali nasičenja presnovne poti UGT1A9.
Biochemical and metabolic laboratory test abnormalities Stivarga has been associated with an increased incidence of electrolyte abnormalities (including hypophosphatemia, hypocalcaemia, hyponatraemia and hypokalaemia) and metabolic abnormalities (including increases in thyroid stimulating hormone, lipase and amylase). 
Odstopanja v izvidih laboratorijskih biokemičnih preiskav in preiskav presnove Zdravilo Stivarga povezujejo z večjo incidenco nenormalnih vrednosti elektrolitov (vključno s hipofosfatemijo, hipokalciemijo, hiponatriemijo in hipokaliemijo) in presnovnimi motnjami (vključno s povečanjem vrednosti tiroideo stimulirajočega hormona, lipaze in amilaze).
Light pink film-coated tablets, oval shaped with a length of 16 mm and a width of 7 mm marked with ‘BAYER' on one side and ‘40' on the other side. 
FARMACEVTSKA OBLIKA filmsko obložena tableta svetlo rožnate filmsko obložene tablete, ovalne oblike, dolžine 16 mm in širine 7 mm, z oznako "BAYER" na eni in "40" na drugi strani
In vitro data indicate that regorafenib as well as its active metabolite M-2 inhibit glucuronidation mediated by UGT1A1 and UGT1A9 whereas M-5 only inhibits UGT1A1 at concentrations which are achieved in vivo at steady state. 
Podatki in vitro kažejo, da regorafenib in njegov aktivni presnovek M-2 zavirata glukuronidacijo z uridindifosfat-glukuroniltransferazama UGT1A1 in UGT1A9, medtem ko M-5 zavira samo UGT1A1 v koncentracijah, ki so dosežene in vivo v stanju dinamičnega ravnovesja.
Of the 760 randomised patients, the median age was 61 years, 61% were male, 78% were Caucasian, and all patients had baseline ECOG Performance Status (PS of 0 or 1. 
Med 760 randomiziranimi bolniki je bila mediana starosti 61 let, 61 % je bilo moških, 78 % je bilo belcev in vsi bolniki so imeli izhodiščni status zmogljivosti (PS - Performance Status) po ECOG 0 ali 1.
There is insufficient data on patients who discontinued sorafenib therapy due to sorafenib-related toxicity or only tolerated a low dose (< 400 mg daily) of sorafenib. 
Podatkov o bolnikih, ki so prenehali zdravljenje s sorafenibom zaradi s sorafenibom povezane toksičnosti, ali so prenašali le nizek odmerek (< 400 mg na dan) sorafeniba, ni dovolj.
The exposure of metabolites M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl) is higher when regorafenib is given with a low fat breakfast, compared to fasting condition and lower when given with a high fat meal, compared to fasting condition. 
Izpostavljenost presnovkoma M-2 (N-oksid) in M-5 (N-oksid in N-dezmetil) je večja, kadar je regorafenib zaužit z zajtrkom, ki vsebuje malo maščob v primerjavi z zaužitjem na tešče, in manjša kadar je zaužit z obrokom, ki vsebuje veliko maščob v primerjavi z zaužitjem na tešče.
Treatment-emergent laboratory abnormalities observed in the placebo-controlled phase III trials are shown in Table 4 and Table 4a (see also section 4.4). 
Odstopanja v izvidih laboratorijskih preiskav, ki so se pojavila med zdravljenjem, in so jih opazili v s placebom nadzorovanih preskušanjih III. faze so navedeni v preglednicah 4 in 4a (glejte tudi poglavje 4.4).
>5 times ULN ≤20 times ULN (Grade 3) 
> 5-kratnik ULN do ≤ 20-kratnik ULN (stopnja 3)
Of the 199 randomised patients, the mean age was 58 years, 64% were male, 68% were Caucasian, and all patients had baseline ECOG Performance Status (PS of 0 or 1. 
Med 199 randomiziranimi bolniki je bila povprečna starost 58 let, 64 % je bilo moških, 68 % je bilo belcev in vsi bolniki so imeli izhodiščni status zmogljivosti (PS - Performance status) po ECOG 0 ali 1.
Reproductive and developmental toxicity 
Vpliv na sposobnost razmnoževanja in razvoja
Important information about some of the ingredients This medicinal product contains 55.8 mg sodium per daily dose of 160 mg, equivalent to 3% of the WHO recommended maximum daily intake of 2 g sodium for an adult.Each daily dose of 160 mg contains 1.68 mg of lecithin (derived from soya). 
To zdravilo vsebuje 55,8 mg natrija na dnevni odmerek (160 mg), kar je enako 3 % največjega dnevnega vnosa natrija za odrasle osebe, ki ga priporoča SZO in znaša 2 g. To zdravilo vsebuje 1,68 mg lecitina (pridobljenega iz soje) na dnevni odmerek (160 mg).
Two major and six minor metabolites of regorafenib have been identified in plasma. 
V plazmi so ugotovili dva glavna in šest manj pomembnih presnovkov.
In case of hypertensive crisis, Stivarga should be discontinued. 
V primeru hipertenzivne krize je treba zdravljenje z zdravilom Stivarga prekiniti.
Table 4: Treatment-emergent laboratory test abnormalities reported in placebo-controlled phase III trials in patients with metastatic CRC (CORRECT), GIST (GRID) and HCC (RESORCE) 
Preglednica 4: Odstopanja v izvidih laboratorijskih preiskav, ki so se pojavila med zdravljenjem, in o katerih so poročali v s placebom nadzorovanem preskušanju III. faze pri bolnikih z metastatskim kolorektalnim rakom (CORRECT), GIST (GRID) in HCC (RESORCE)
Stivarga should be permanently discontinued if there is no resolution. 
Zdravljenje z zdravilom Stivarga je treba trajno prenehati, če se stanje ne izboljša.
Gender The pharmacokinetics of regorafenib is not influenced by gender. 
Spol Spol ne vpliva na farmakokinetiko regorafeniba.
The Asian patients treated with Stivarga in clinical studies were primarily from East Asia (~90%). 
V kliničnih študijah je bila večina bolnikov azijske rase, zdravljenih z zdravilom Stivarga, iz vzhodne Azije (~ 90 %).
The most frequently observed adverse drug reactions (≥30%) in patients receiving Stivarga are pain, hand foot skin reaction, asthenia/fatigue, diarrhoea, decreased appetite and food intake, hypertension and infection. 
Najpogosteje opaženi neželeni učinki (≥ 30 %) pri bolnikih, ki prejemajo zdravilo Stivarga, so bolečina, kožna reakcija na dlaneh in podplatih, astenija/utrujenost, driska, zmanjšan apetit in vnos hrane, hipertenzija in okužba.
The concentration-time profile indicates that regorafenib and its metabolites may undergo enterohepatic circulation (see section 5.2). 
Profil koncentracije v odvisnosti od časa kaže, da lahko regorafenib in njegovi presnovki prehajajo v enterohepatični obtok (glejte poglavje 5.2).
No dose adjustment is necessary based on gender (see also section 5.2). 
Odmerka ni treba prilagajati glede na spol (glejte tudi poglavje 5.2).
Patients were eligible to participate in the study if they experienced radiological disease progression during treatment with sorafenib and if they had a liver function status of Child-Pugh class A. Patients who permanently discontinued sorafenib therapy due to sorafenib-related toxicity or who tolerated less than 400 mg sorafenib once daily prior to withdrawal were excluded from the study. 
Povprečni dnevni odmerek regorafeniba je bil 144 mg. Bolniki so bili primerni za vključitev v študijo, če je pri njih prišlo do radiološko potrjenega napredovanja bolezni med zdravljenjem s sorafenibom in če so imeli okvaro jeter opredeljeno kot Child-Pugh A. Bolniki, ki so trajno prenehali zdravljenje s sorafenibom zaradi s sorafenibom povezane toksičnosti, ali so bili pred prenehanjem zdravljenja odmerki sorafeniba, ki so jih prenašali manjši kot 400 mg enkrat na dan, so bili izključeni iz študije.
Whereas plasma concentrations of M-2 and M-5 after a single dose of regorafenib are much lower than those of parent compound, steady-state plasma concentrations of M-2 and M-5 are comparable to those of regorafenib. 
Medtem ko so plazemske koncentracije M-2 in M-5 po enkratnem odmerku regorafeniba precej manjše kot koncentracije izhodne spojine, so plazemske koncentracije M-2 in M-5 v stanju dinamičnega ravnovesja primerljive s koncentracijami regorafeniba.
In vitro data indicate that regorafenib is a competitive inhibitor of the cytochromes CYP2C8 (Ki value of 0.6 micromolar), CYP2C9 (Ki value of 4.7 micromolar), CYP2B6 (Ki value of 5.2 micromolar) at concentrations which are achieved in vivo at steady state (peak plasma concentration of 8.1 micromolar). 
Podatki in vitro kažejo, da je regorafenib kompetitivni zaviralec citokroma CYP2C8 (vrednost Ki 0,6 mikromolarna), CYP2C9 (vrednost Ki 4,7 mikromolarna), CYP2B6 (vrednost Ki 5,2 mikromolarna) pri koncentracijah, ki so dosežene in vivo v stanju dinamičnega ravnovesja (največja plazemska koncentracija 8,1 mikromolarna).
In clinical studies, no relevant differences in exposure, safety or efficacy were observed between male and female patients. 
V kliničnih študijah niso opazili pomembnih razlik v izpostavljenosti, varnosti ali učinkovitosti med bolniki in bolnicami.
Table 6: Efficacy results from the GRID study Efficacy parameter 
Preglednica 6: Rezultati študije GRID glede učinkovitosti
Patients continued therapy until disease progression or unacceptable toxicity. 
Bolniki so z zdravljenjem nadaljevali do napredovanja bolezni ali nesprejemljivih škodljivih učinkov.
Subgroup analysis results by historical KRAS mutational status showed a treatment effect for OS in favour of regorafenib over placebo for patients with KRAS wild-type tumours whereas a numerically lower effect was reported in patients with KRAS mutant tumours; the treatment effect for PFS favouring regorafenib was observed regardless of KRAS mutational status. 
Rezultati analize podskupin z mutacijo gena KRAS v anamnezi so pokazali terapevtski učinek za celokupno preživetje v korist regorafeniba v primerjavi s placebom za bolnike s tumorji z divjim tipom gena KRAS, medtem ko so poročali o numerično manjšem učinku pri bolnikih s tumorji z mutacijo gena KRAS; terapevtski učinek za preživetje brez napredovanja bolezni je bil v korist regorafeniba ne glede na status mutacije gena KRAS.
The concentrations of regorafenib and its major pharmacologically active metabolites (M-2 and M-5) were highest when given after a low-fat (light) breakfast, compared to either a high-fat breakfast or fasting condition. 
Koncentracije regorafeniba in njegovih glavnih farmakološko aktivnih presnovkov (M-2 in M-5) so bile največje, če je bilo zdravilo zaužito po zajtrku z majhno vsebnostjo maščob (lahkem zajtrku) v primerjavi z zajtrkom z veliko vsebnostjo maščob ali na tešče.
Therapies included treatment with fluoropyrimidine-based chemotherapy, an anti-VEGF therapy, and, if the patient was KRAS wild type, an anti-EGFR therapy. 
Zdravljenja so vključevala zdravljenje s kemoterapijo na osnovi fluoropirimidina, zdravljenje z zaviralci VEGF in, pri bolnikih z divjim tipom gena KRAS, zdravljenje z zaviralci EGFR.
- if you get an infection with signs such as high fever, severe cough with or without an increase in mucus (sputum) production, severe sore throat, shortness of breath, burning/pain when urinating, unusual vaginal discharge or irritation, redness, swelling and/or pain in any part of the body. 
- če imate okužbo z znaki kot so visoka telesna temperatura, hud kašelj z ali brez povečanega nastajanja sluzi (sputum), hudo vnetje grla, kratka sapa, pekoča bolečina/bolečine pri uriniranju, neobičajen izcedek iz nožnice ali draženje, rdečina, otekanje in/ali bolečina v katerem koli delu telesa.
Increased Amylase a Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 b Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 
b skupni kriteriji za terminologijo neželenih učinkov (CTCAE - Common Terminology Criteria for Adverse Events), različica 4.0
10.6 months 
10,6 mesecev
No dose adjustment is necessary based on ethnicity (see section 5.2). 
Odmerka ni treba prilagajati glede na etnično skupino (glejte poglavje 5.2).
Secondary endpoints were Progression-Free Survival (PFS), Objective Tumour Response Rate (ORR) and Disease Control Rate (DCR). 
Sekundarni cilji učinkovitosti so bili preživetje brez napredovanja bolezni (PFS - Progression Free Survival), objektivna stopnja tumorskega odziva (ORR - Objective Tumour Response Rate) in stopnja nadzora nad boleznijo (DCR - Disease Control Rate).
Major human metabolites (M-2 and M-5) exhibited similar efficacies, compared to regorafenib in in vitro and in vivo models. 
Glavni presnovki pri ljudeh (M-2 in M-5) so, v primerjavi z regorafenibom, kazali podobne učinke v in vitro ter in vivo modelih.
There is no relevant use of Stivarga in children and adolescents in the indication of colon or rectal cancer that has spread to other parts of the body. 
Zdravilo Stivarga ni namenjeno za uporabo pri otrocih in mladostnikih za indikacijo raka debelega črevesa ali danke, ki se je razširil na druge dele telesa.
Breast cancer resistance protein (BCRP) and P-glycoprotein substrates Administration of regorafenib (160 mg for 14 days) prior to administration of a single dose of rosuvastatin (5 mg), a BCRP substrate, resulted in a 3.8-fold increase in mean exposure (AUC) of rosuvastatin and a 4.6-fold increase in Cmax. 
Protein odpornosti za raka dojke (BCRP - Breast Cancer Resistance Protein) in substrati glikoproteina P Uporaba regorafeniba (160 mg 14 dni) pred administracijo enkratnega odmerka rosuvastatina (5 mg), substrata BCRP, povzroči 3,8-kratno povečanje povprečne izpostavljenosti (AUC) rosuvastatina in 4,6-kratno povečanje Cmax.
In clinical trials, a higher incidence of severe liver injury with fatal outcome was observed in Japanese patients (~1.5%) treated with Stivarga, compared with nonJapanese patients (<0.1%). 
V kliničnih preskušanjih so večjo incidenco hude okvare jeter s smrtnim izidom opazili pri japonskih bolnikih (~1,5 %), zdravljenih z zdravilom Stivarga, v primerjavi z nejaponskimi bolniki
Hand-foot skin reaction (HFSR) or palmar-plantar erythrodysesthesia syndrome and rash represent the most frequently observed dermatological adverse reactions with Stivarga (see section 4.8). 
Kožne reakcije na dlaneh in podplatih (HFSR - hand-foot skin reaction) ali sindrom palmarno-plantarne eritrodisestezije in izpuščaj sta najpogostejša neželena učinka na koži pri uporabi zdravila Stivarga (glejte poglavje 4.8).
Most infections in patients treated with Stivarga were mild to moderate in severity (Grades 1 and 2: 23.0%), and included urinary tract infections (5.7%), nasopharyngitis (4.0%), mucocutaneous and systemic fungal infections (3.3%) as well as pneumonia (2.6%). 
Večina okužb pri bolnikih, zdravljenih z zdravilom Stivarga, je bilo blagih do zmernih (stopnje 1 in 2: 23,0 %), in so vključevale okužbe sečil (5,7 %), nazofaringitis (4,0 %), mukokutane in sistemske glivične okužbe (3,3 %) kot tudi pljučnico (2,6 %).
Efficacy parameter 
Kazalci učinkovitosti
Increased ALT 
Starejši
The hazard ratio (95% CI) of OS was 0.653 (0.476 to 0.895) for patients with KRAS wild-type tumours and 0.867 (0.670 to 1.123) for patients with KRAS mutant tumours, with no evidence of heterogeneity in treatment effect (non-significant interaction test). 
Razmerje ogroženosti (95 % IZ) celokupnega preživetja je bilo 0,653 (0,476 do 0,895) pri bolnikih s tumorjem z divjim tipom gena KRAS in 0,867 (0,670 do 1,123) pri bolnikih s tumorjem z mutacijo gena KRAS, brez dokaza heterogenosti v terapevtskem učinku (nesignifikanten interakcijski test).
Table 7: Efficacy results from the RESORCE study 
Preglednica 7: Rezultati študije RESORCE glede učinkovitosti
(hypersensitivity reaction) - heart attack, chest pain (myocardial infarction and ischaemia) - severely elevated blood pressure causing headache, confusion, blurry vision, nausea, vomiting, 
(preobčutljivostna reakcija) - srčni napad, bolečina v prsnem košu (srčni infarkt in ishemija srca) - izrazito zvišan krvni tlak, ki povzroči glavobol, zmedenost, zamegljen vid, siljenje na bruhanje
In clinical studies, no relevant differences in exposure, safety or efficacy were observed between patients with mild hepatic impairment (Child-Pugh A) and normal hepatic function. 
V kliničnih študijah niso opazili klinično pomembnih razlik v izpostavljenosti, varnosti in učinkovitosti med bolniki z blago okvaro jeter (Child-Pugh A) in bolniki z normalnim delovanjem jeter.
An effect of regorafenib on intrauterine development was shown in rabbits at exposures below the anticipated human exposure (based on AUC comparison). 
Pri kuncih je regorafenib pokazal vpliv na intrauterini razvoj pri izpostavljenosti, ki je bila manjša od pričakovane izpostavljenosti pri ljudeh (glede na primerjavo AUC).